文献速递肿瘤 PET/CT核素与放射性配体治疗

[68Ga]Ga-FAPI-04 PET/CT在肾细胞癌中的作用:一项初步研究

The role of [68 Ga]Ga-FAPI-04 PET/CT in renal cell carcinoma: a preliminary study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-10-07

本研究纳入20例疑似原发性肾恶性肿瘤或有肾细胞癌病史的患者,其中18例可分析,6例为新诊断、12例为再分期,所有患者均接受[68Ga]Ga-FAPI-04与[18F]F-FDG PET/CT。结果显示所有病灶的FAPI-PET/CT中位TBR高于FDG-PET/CT(5.6 vs 2.1,p<0.001),肺部病灶FAPI中位SUVmax亦显著高于FDG(3.8 vs 1.8,p=0.02)。作者认为[68Ga]Ga-FAPI-04 PET/CT在肾细胞癌中显示出潜在应用价值。

要点

  • 所有病灶FAPI-PET/CT中位TBR高于FDG-PET/CT(5.6 vs 2.1,p<0.001)。
  • 肺部病灶FAPI中位SUVmax显著高于FDG(3.8 vs 1.8,p=0.02)。
  • 49%病灶FAPI-SUVmax≥6,13%病灶FAPI-SUVmax≥10。

核心结论

  • 本研究显示[68Ga]Ga-FAPI-04 PET/CT在肾细胞癌中显示出潜在应用价值,结果令人鼓舞。
  • 作者推测FAPI-PET/CT可作为补充影像手段,在选定患者中提供预后信息及诊疗一体化应用的可能性。

研究设计与样本

  • 本研究纳入20例疑似原发性肾恶性肿瘤或有肾细胞癌病史的患者,其中2例因确诊其他恶性肿瘤被排除进一步分析。
  • 6例为新诊断,12例的检查指征为再分期;所有患者均接受[68Ga]Ga-FAPI-04与[18F]F-FDG PET/CT。
  • 比较原发灶(n=7)、局部复发灶(n=6)及淋巴结(n=26)、肺(n=32)、骨(n=5)和其他转移灶(n=14)的SUVmax与肿瘤/本底比值(TBR)。

主要发现

  • 在18例患者中共检测到90个病灶,两种PET/CT上FAPI与FDG摄取值存在差异。
  • 所有病灶FAPI-PET/CT中位TBR高于FDG-PET/CT中位TBR(5.6 vs 2.1,p<0.001),差异有统计学意义。
  • 原发和复发病灶中,FAPI-PET/CT的中位SUVmax、TBR及肿瘤体积均高于FDG-PET/CT。
  • 肺部病灶FAPI-PET/CT中位SUVmax显著高于FDG中位SUVmax(3.8 vs 1.8,p=0.02)。
  • 基于TNM分期,早期原发病灶FAPI-SUVmax中位数低于晚期。

关键数值与推荐

  • 全部病灶中49%的FAPI-SUVmax≥6,13%的FAPI-SUVmax≥10。
  • 基于患者的分析中,7例(39%)患者至少有一个病灶FAPI-SUVmax≥10;12例(67%)患者至少有一个病灶FAPI-SUVmax≥6。

临床怎么用

  • 作者推测FAPI-PET/CT可作为补充影像手段,在选定患者中提供预后信息及诊疗一体化应用的可能性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We aimed to investigate the role of [68 Ga]Ga-FAPI-04 PET/CT and uptake patterns of primary and metastatic lesions in patients with renal cell carcinoma (RCC). METHODS: Twenty patients with a suspicious lesion considered primary renal malignancy or a history of RCC were included in our study. Two patients were excluded from further analyses due to other confirmed malignancies. Six patients were newly diagnosed, while the indication of 12 patients was restaging. All patients underwent [68 Ga]Ga-FAPI-04 and [18F]F-FDG PET/CT. SUVmax and tumor-to-background ratio (TBR) of primary (n = 7) and local recurrent lesions (n = 6) and lymph node (n = 26), lung (n = 32), bone (n = 5), and other metastases (n = 14) were compared between the two tracers. RESULTS: We detected 90 lesions in 18 patients with varying FAPI and FDG uptake values on both PET/CT. The median TBR of FAPI-PET/CT of all lesions was higher than TBR of FDG-PET/CT with statistically significance (5.6 vs. 2.1, p < 0.001). In primary and recurrent lesions, the median SUVmax, TBR, and tumor volume on FAPI-PET/CT were higher than FDG-PET/CT. The median SUVmax of lung lesions on FAPI-PET/CT was statistical significantly higher than FDG-SUVmax (3.8 vs. 1.8, p = 0.02). The median of FAPI-SUVmax on primary lesions was lower in the early stage based on TNM compared to the advanced stage. FAPI-SUVmax in 49% of all lesions were SUVmax ≥ 6, and 13% were SUVmax ≥ 10. In patient-based analyses, seven patients (39%) had at least one lesion with FAPI-SUVmax ≥ 10; 12 patients (67%) had at least one lesion with FAPI-SUVmax ≥ 6. CONCLUSION: This study showed the potential utility of [68 Ga]Ga-FAPI-04 PET/CT showing promising results in RCC. We have presumed that FAPI-PET/CT may be performed for complementary imaging modality providing prognosis and possibility of theranostic application in selected patients.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Civan C, Kuyumcu S, Has Simsek D, et al. The role of [68 Ga]Ga-FAPI-04 PET/CT in renal cell carcinoma: a preliminary study. Eur J Nucl Med Mol Imaging. 2023. PMID: 37803246. doi:10.1007/s00259-023-06461-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。